#ObesityWeek
An investigational oral quadruple receptor agonist led to substantial weight loss with preservation of lean mass, a randomized phase II trial presented at #OW26 #ObesityWeek showed.
https://www.medpagetoday.com/meetingcoverage/obesityweek/123955
Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage Trial
Once-daily oral agent also showed favorable tolerability
www.medpagetoday.com
November 18, 2026 at 9:19 PM
How many of us this week trying to ricochet between #obesityweek #TOS & @sfn.org in DC?? 🧪🧪
November 15, 2026 at 4:06 PM
Day 3 at #ObesityWeek 2026 connected:
🧠 Gut-brain signaling and why dietary adherence is not simply willpower.
🦴 Body composition, strength, and independence in older adults.
🧬 Menopause and the metabolic effects of estrogen signaling.

My recap: www.linkedin.com/pulse/obesit...
ObesityWeek 2026 Day 3: The Scale Is an Output
Day 3 at #ObesityWeek 2026 was my favorite kind of conference day. The morning was gut-brain neuroscience, the afternoon was clinical care for older adults, and the day closed with menopause and hormo...
www.linkedin.com
November 17, 2026 at 1:24 PM
An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial. #ObesityWeek #OW2026 @obesitysociety.bsky.social
https://www.medpagetoday.com/meetingcoverage/obesityweek/123896
GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia
LUCIDITY trial supports GLP-1 receptor signaling as a central driver of PBH pathophysiology
www.medpagetoday.com
November 17, 2026 at 5:55 AM
When should emerging science enter clinical care?

Acosta’s talk was my Day 2 highlight at #ObesityWeek: matching treatment to biology, with new work on appetite, maintenance, and body composition.

Waiting has consequences too.

www.linkedin.com/pulse/obesit...
ObesityWeek 2026, Day 2: Bringing the Science Into Care
Day 1 at #ObesityWeek 2026 asked how we define success in obesity care. Day 2 asked a related question: what can we learn about a person's biology and experience that helps us choose, and sustain, the...
www.linkedin.com
November 16, 2026 at 4:06 PM
At #ObesityWeek and in @nejm.org, STEP Young offers evidence that effective medical treatment can change the trajectory. This is something worth celebrating, #OW2026
conscienhealth.org/2026/11/17/o...
November 17, 2026 at 11:32 AM
If you’re at #obesityweek 🧪🧪, I’ll talk this afternoon about targeting safer #estrogen signaling in both sexes across #aging / #menopause to improve #metabolic health and halt #neurodegeration, including #neuropathy. Article here: www.theobesitysocietynews.org/kristy-towns...
Kristy Townsend, PhD, Considers Role of Menopause in Metabolic Health - The Obesity Society News
Key Lecture will explore ongoing research into estrogen therapies for metabolic and peripheral nerve health.
www.theobesitysocietynews.org
November 16, 2026 at 3:40 PM
Are you attending @ObesityWeek® 2026?

EASO President Volkan Yumuk and Tryggvi Helgason look forward to seeing you there!

✅Learn about the latest developments in evidence-based obesity science and clinical management

Stop by and see us at booth 545!👏

obesityweek.org
Innovative Science to Transformational Care
ObesityWeek® is the premier international conference for obesity researchers and clinicians, showcasing the most recent advances in evidence‑based obesity science—including cutting‑edge basic and…
obesityweek.org
November 14, 2026 at 1:30 PM
Fat loss without muscle loss — and a jab just once or twice a year? The new drug taking over ObesityWeek 2026. Full story: scoopmint.blogspot.com #ObesityWeek
ScoopMint — Fresh news first
Fresh news first. Crypto, celebrity and fitness — the hottest stories, daily.
scoopmint.blogspot.com
November 14, 2026 at 5:06 AM
Biotech catalysts today (Tue Nov 17)
$ACAD data readout
$CRBP presents at ObesityWeek (CRB-913)
$CRDF conference presentation (Onvansertib)
+2 more on the site
Dates from the companies' SEC filings
#Biotech #Stocks

Visit for more info: www.elixstocks.com
Educational only. Not investment advice.
Biotech catalysts today — ElixStocks
$ACAD data readout; $CRBP presents at ObesityWeek (CRB-913); $CRDF conference presentation (Onvansertib); $GPCR presents at ObesityWeek
elixstocks.com
November 17, 2026 at 12:15 PM
Eli Lilly & Co on Saturday released some new data from several clinical trials of its obesity drugs for the ObesityWeek 2026 medical conference, but it has not yet released the full results.
Lilly says its obesity drugs helped patients lose weight in clinical trials
Eli Lilly & Co on Saturday released some new data from several clinical trials of ​its obesity drugs for the ObesityWeek 2026 ‌medical conference, but it has not yet released the full results.
reut.rs
November 14, 2026 at 5:45 PM
Today as #ObesityWeek starts, we have two rich paths to follow on health policy. Are they parallel? Or do they intersect in surprising ways?
#OW2026
conscienhealth.org/2026/11/14/c...
November 14, 2026 at 11:18 AM
This #ObesityWeek seemed like a milestone in many ways. Advances in evidence to support pediatric obesity care and the sheer scope and scale of the meeting are top of mind. We're still processing, but here are 5 themes that stand out. #OW2026
conscienhealth.org/2026/11/18/s...
November 18, 2026 at 11:22 AM
Heading to #ObesityWeek® on 14–17 November 2026 in Washington DC 🇺🇸?

🤝🏽 Meet our MPP team attending #ObesityWeek2026: Natacha Debbané and Romain Dissard - @romaindissard.bsky.social

📩 Get in touch with our team to arrange a conversation!

#ObesityWeek #OW2026
November 12, 2026 at 3:22 PM
📅 Coming up in the obesity community: 🇺🇸 ObesityWeek (14–17 Nov), 🇪🇸 The Lancet Summit on Diabetes Prevention (30 Nov–2 Dec), 🇨🇳 SCOPE Masterclass China (from 5 Dec) and 🇮🇳 SCOPE School India (11 Dec).
➡️ See all events: https://ow.ly/JHQk5106now
#ObesityCommunity #GlobalHealth #ObesityPolicy
November 17, 2026 at 1:00 PM
Lilly says its obesity drugs helped patients lose weight in clinical trials reut.rs/4zQo8tI
Lilly says its obesity drugs helped patients lose weight in clinical trials
Eli Lilly & Co on Saturday released some new data from several clinical trials of ​its obesity drugs for the ObesityWeek 2026 ‌medical conference, but it has not yet released the full results.
reut.rs
November 14, 2026 at 5:15 PM
Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, a phase III trial showed. #obesityweek #ow2026 @obesitysociety.bsky.social https://www.medpagetoday.com/meetingcoverage/obesityweek/123891
Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial
Over half of SURMOUNT-ADOLESCENTS patients no longer met clinical threshold for obesity
www.medpagetoday.com
November 16, 2026 at 10:24 PM
In a phase 3, double-blind, randomized trial involving 167 children (6 to <12 years of age) with obesity, treatment with semaglutide resulted in a significantly greater reduction in BMI than placebo. Full STEP Young trial results: https://nej.md/4ArUURG

#ObesityWeek | @obesitysociety.bsky.social
November 16, 2026 at 3:05 PM
Understanding obesity starts with listening to the people living with it.
At #ObesityWeek 2026, we’re bringing people and science together to explore the questions shaping obesity care.
bit.ly/4z5kwn6

#OW2026
November 13, 2026 at 3:36 PM